Capture-Based Targeted Ultradeep Sequencing in Paired Tissue and Plasma Samples Demonstrates Differential Subclonal ctDNA-Releasing Capability in Advanced Lung Cancer

Journal of Thoracic Oncology

Volumn 12, Issue 4, 2017, Pages 663-672

  Mao, Xiaowei ^a   Zhang, Zhou ^b   Zheng, Xiaoxuan ^a   Xie, Fangfang ^a   Duan, Feidie ^b   Jiang, Liyan ^a   Chuai, Shannon ^b   Han Zhang, Han ^b   Han, Baohui ^a   Sun, Jiayuan ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Burning Rock Biotech ^*  (China)

Author keywords

Capture based targeted sequencing; ctDNA; Liquid biopsy; Lung cancer; Releasing capability

Indexed keywords

CIRCULATING TUMOR DNA; DNA; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER GENETICS; CANCER PATIENT; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE DELETION; GENE FUSION; GENE INSERTION; GENE MUTATION; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRON; LUNG BIOPSY; MALE; MOLECULAR CLONING; MUTATIONAL ANALYSIS; NON SMALL CELL LUNG CANCER; NORMALIZED RELATIVE ALLELIC FRACTION SCORE; SCORING SYSTEM; ADENOCARCINOMA; BLOOD; CANCER STAGING; FOLLOW UP; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; PROGNOSIS; SECONDARY; SMALL CELL LUNG CANCER; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; SMALL CELL LUNG CARCINOMA;

EID: 85015836654     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.11.2235     Document Type: Article

References (30)

1. 1 Hiley, C., de Bruin, E.C., McGranahan, N., Swanton, C., Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine. Genome Biol, 15, 2014, 453.
2. 2 Yates, L.R., Gerstung, M., Knappskog, S., et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med 21 (2015), 751–759.
3. 3 Zhang, J., Fujimoto, J., Zhang, J., et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346 (2014), 256–259.
4. 4 Chabon, J.J., Simmons, A.D., Lovejoy, A.F., et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun, 7, 2016, 11815.
5. 5 Piotrowska, Z., Niederst, M.J., Karlovich, C.A., et al. Heterogeneity underlies the emergence of EGFRT790 wild-type clones following treatment of T790M-positive cancers with a third-generation EGFR inhibitor. Cancer Discov 5 (2015), 713–722.
6. 6 Cai, W., Lin, D., Wu, C., et al. Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocarcinoma. J Clin Oncol 33 (2015), 3701–3709.
7. 7 Suda, K., Murakami, I., Yu, H., et al. Heterogeneity of EGFR aberrations and correlation with histological structures: analyses of therapy-naive isogenic lung cancer lesions with EGFR mutation. J Thorac Oncol 11 (2016), 1711–1717.
8. 8 Maemondo, M., Inoue, A., Kobayashi, K., et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362 (2010), 2380–2388.
9. 9 Tan, C.S., Gilligan, D., Pacey, S., Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. Lancet Oncol 16 (2015), e447–e459.
10. 10 Mazieres, J., Zalcman, G., Crino, L., et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 33 (2015), 992–999.
11. 11 Shaw, A.T., Ou, S.H., Bang, Y.J., et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371 (2014), 1963–1971.
12. 12 Ohtsuka, K., Ohnishi, H., Furuyashiki, G., et al. Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma. J Thorac Oncol 1 (2006), 787–795.
13. 13 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/lung_screening.pdf. Accessed December 29, 2016.
14. 14 Fukuoka, M., Wu, Y.L., Thongprasert, S., et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29 (2011), 2866–2874.
15. 15 Douillard, J.Y., Shepherd, F.A., Hirsh, V., et al. Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. J Clin Oncol 28 (2010), 744–752.
16. 16 Brugger, W., Triller, N., Blasinska-Morawiec, M., et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29 (2011), 4113–4120.
17. 17 Alix-Panabieres, C., Pantel, K., Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov 6 (2016), 479–491.
18. 18 Haber, D.A., Velculescu, V.E., Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov 4 (2014), 650–666.
19. 19 Bettegowda, C., Sausen, M., Leary, R.J., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med, 6, 2014 224ra24.
20. 20 Newman, A.M., Bratman, S.V., To, J., et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20 (2014), 548–554.
21. 21 Lipson, D., Capelletti, M., Yelensky, R., et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 18 (2012), 382–384.
22. 22 Rachiglio AM, Abate RE, Sacco A, et al. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma [e-pub ahead of print]. Oncotarget. http://dx.doi.org/10.18632/oncotarget.10704, accessed December 29, 2016.
23. 23 Heitzer, E., Ulz, P., Geigl, J.B., Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem 61 (2015), 112–123.
24. 24 Maheswaran, S., Sequist, L.V., Nagrath, S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359 (2008), 366–377.
25. 25 Ono, S., Lam, S., Nagahara, M., Hoon, D.S., Circulating microRNA biomarkers as liquid biopsy for cancer patients: pros and cons of current assays. J Clin Med 4 (2015), 1890–1907.
26. 26 Yung, T.K., Chan, K.C., Mok, T.S., Tong, J., To, K.F., Lo, Y.M., Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 15 (2009), 2076–2084.
27. 27 Carpagnano, G.E., Foschino-Barbaro, M.P., Spanevello, A., et al. 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer. Am J Respir Crit Care Med 177 (2008), 337–341.
28. 28 Esteller, M., CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21 (2002), 5427–5440.
29. 29 Taniguchi, K., Okami, J., Kodama, K., Higashiyama, M., Kato, M., Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99 (2008), 929–935.
30. 30 Crowley, E., Di Nicolantonio, F., Loupakis, F., Bardelli, A., Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10 (2013), 472–484.